The manufacturers reportedly cut down the production as the profit margin for stand-alone hepatitis B vaccine is lower. There are also reports about a dearth of raw materials.
The manufacturers reportedly cut down the production as the profit margin for stand-alone hepatitis B vaccine is lower. There are also reports about a dearth of raw materials.